drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous dual-target CAR-T cell therapy in which a patient’s T cells are engineered to express chimeric antigen receptors recognizing CD19 and CD20 on B cells, triggering CD3ζ-based signaling with costimulation to induce cytokine release and cytotoxic killing; dual targeting aims to limit antigen escape in B‑cell malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express dual CARs recognizing CD19 and CD20 on B cells. Antigen engagement triggers CD3ζ signaling with costimulation, activating and expanding the T cells to secrete cytokines and mediate cytotoxic killing of malignant B cells; dual targeting is intended to limit antigen escape.
drug_name
LUCAR-G39P
nct_id_drug_ref
NCT06295549